Key result
Bio-Medicus centrifugal pump associated with ~40% survival to discharge in refractory postcardiotomy heart failure.
Why the study?
Does the Bio-Medicus centrifugal pump improve survival in patients with refractory postcardiotomy heart failure?
Observational (n=10)
Does the Bio-Medicus centrifugal pump improve survival in patients with refractory postcardiotomy heart failure?
Answers are grounded in this paper and cite their sources.
The Bio-Medicus centrifugal pump can successfully support a subset of patients with refractory postcardiotomy heart failure, though hemorrhagic and renal complications are common and often fatal.
Between January 1990 and September 1992, ten patients required assisted circulation for postcardiotomy heart failure which was unresponsive to inotropic drugs and aortic counterpulsation. All patients were supported by a Bio-Medicus centrifugal pump (biventricular assist in Ave, left ventricular in three, right ventricular in two); six had ischaemic heart disease, two a congenital ventricular septal defect, one an acute mitral valve incompetence and one an aortic type ‘A’ dissection. The mean duration of circulatory support was 5.1 days (range 2 hours to 8 days). Six patients were weaned from the device and four were discharged; the perioperative deaths among the patients weaned from support were the result of cerebral haemorrhage and multiorgan failure respectively. No late deaths occurred at a mean follow-up of 15 months. Common complications were bleeding (40%), acute renal failure (30%) and sepsis (30%). All patients who developed renal failure died. The high incidence of haemorrhagic complications makes the use of pre-heparinized circuits desirable as these patients do not then require additional anticoagulation.
No takes yet. Share an insight, caveat, or question.
Paolini et al. (1994) conducted an observational in Postcardiotomy heart failure (n=10). Bio-Medicus centrifugal pump was evaluated on Survival to discharge. Support with the Bio-Medicus centrifugal pump in 10 patients with refractory postcardiotomy heart failure resulted in 60% being weaned from the device and 40% surviving to discharge.
Synapse has enriched 10 related papers. Consider them for comparative context: